Adult Sickle Cell Care: Find a Center and Survive a Pain Crisis

In the Dallas Newborn Cohort, 93.9% of children with sickle cell anemia lived to become adults, and every recent death in the cohort happened at age 18 or older, most shortly after the move to adult care (Quinn et al., Blood, 2010). National death certificates show the same cliff: sickle cell mortality rises from 0.6 per 100,000 at ages 15 to 19 to 1.4 per 100,000 at ages 20 to 24, the exact years patients leave pediatric hematology (Hamideh and Alvarez, 2013). The adult system they enter is thin. Access to adult sickle cell care is poor in many parts of the country, and a shortage of non-malignant hematology providers compounds it (Kanter et al., Blood Advances, 2020). Sickle cell disease affects about 100,000 people in the United States, more than 90% of them Black, and occurs in about 1 of every 365 Black births, per the CDC data page dated May 15, 2024. This guide is for the adult standing in that gap.

The emergency room becomes the default clinic at exactly the wrong age. In state Medicaid data on 3,208 patients, reliance on the ER for care started climbing at age 15, rose from 0.17 to 0.29 visits per quarter by age 22, and stayed high through adulthood; patients leaned on the ER most in the period right after transition (Blinder et al., Journal of Emergency Medicine, 2015). The gap itself is the risk factor. At one comprehensive program, young adults whose gap between the last pediatric visit and the first adult visit was six months or longer had 2.01 times the hospitalization rate of those transferred within two months, and 1.75 times the rate of ER encounters in the first two years of adult care (Howell et al., Blood Advances, 2024).

Adults are living longer with the disease and dying of it later. Across 25,665 sickle cell related deaths among Black Americans from 1979 to 2017, the death rate fell in children and rose in adults, the median age at death climbed from 28 to 43, and deaths shifted toward chronic heart, lung, and kidney complications (Payne et al., Annals of Emergency Medicine, 2020). The CDC puts life expectancy with the disease at more than 20 years shorter than average. The workforce has not caught up: in a national survey of academic family physicians, 20.4% felt comfortable treating sickle cell disease (Mainous et al., 2015), and a majority of primary care providers surveyed at Johns Hopkins Community Physicians lacked confidence in all four domains measured, including chronic pain (Whiteman et al., 2015). The 2020 National Academies report names "the current dearth of hematologists with SCD expertise" outright. The rule that falls out of Howell's data: the transfer gap is the one variable you control. Ask your pediatric team for a named adult clinic and a first appointment date before your final pediatric visit, and treat a gap longer than six months as an emergency of its own.

The word "center" is not regulated, so use the definition adult programs wrote for themselves. A 2020 consensus of 14 established adult centers set the minimum: a physician lead who is a sickle cell specialist and comfortable with evidence-based pain management, one or more social workers, a patient navigator or case manager, dedicated nursing staff, and the ability to deliver acute and chronic pain management, transfusion including apheresis, and timely access to other specialists. Most centers also run an infusion center or day hospital, where a crisis is treated without an ER visit; a center without one is expected to have prespecified individualized care plans and a designated place to treat you (Kanter et al., 2020). If a program cannot name its social worker, its navigator, and where you go at 2 a.m., it is not a sickle cell center.

1. The NASCC directory. The National Alliance of Sickle Cell Centers' find-a-center map labels each member center adult, pediatric, or whole-life. Its adult center criteria, read August 25, 2026, require a sickle cell specialist physician, a case manager or navigator, social workers, nurses educated in the disease, written procedures for acute, chronic, and pain management, erythrocytapheresis, timely transfusion medicine, specialist access including family planning, a mental health plan, and access to every approved disease-modifying therapy. That is the vetting done for you.

2. Our hematology directory. Find a Black hematologist by state and city, then ask whether the practice is attached to an adult program.

3. SCDAA. The SCDAA member finder lists community organizations, not clinics, but they know which hospitals run adult programs and many provide navigators. The helpline is (800) 421-8453.

When you call, ask five things: Is there an adult sickle cell clinic with a named specialist? An infusion center or day hospital for crises? Will you write an individualized pain plan and put it in the hospital's electronic record? Do you take my insurance or Medicaid? How soon is the first visit? Bring your pediatric records: baseline hemoglobin, transfusion history and red cell antibodies, your hydroxyurea dose, and the pain regimens that have and have not worked.

The standard is written down. The American Society of Hematology's 2020 pain guideline states: "For adults and children with SCD presenting to an acute care setting with acute pain related to SCD, the ASH guideline panel recommends rapid (within 1 hour of ED arrival) assessment and administration of analgesia with frequent reassessments (every 30 to 60 minutes) to optimize pain control." It is graded a strong recommendation, the panel's highest (Brandow et al., Blood Advances, 2020). The same guideline suggests opioid dosing tailored to your baseline use and what has worked before rather than weight-based dosing, a short course of NSAIDs alongside opioids when your kidneys allow, and subcutaneous or intranasal routes to get the first dose in when IV access is slow.

The measured reality misses the hour. Across 612 adult ER visits at multiple centers, the median time to a first analgesic was 90 minutes, women waited a mean 21 minutes longer, and patients given a lower triage level waited 45 minutes longer (Tanabe et al., Academic Emergency Medicine, 2007). Attitude is part of the delay: among 722 emergency providers surveyed, those with the most negative attitudes toward sickle cell patients were 20% less likely to redose opioids within 30 minutes when pain was uncontrolled (Glassberg et al., 2013). Among 291 adults with the disease, difficulty persuading providers about pain was tied to perceived discrimination, and disease-based discrimination went with a heavier daily pain burden (Haywood et al., 2014). Our guides on ER wait times and advocacy and the pain-tolerance myth cover that bias in depth.

The guideline defines the tool: "Individualized care plans, developed with acute care and SCD care providers, are treatment recommendations that include medications and doses that are effective for a given patient. These plans can be embedded in the electronic medical record and used to guide opioid dosing" (Brandow et al., 2020). A usable plan fits on one page: genotype, baseline hemoglobin, home regimen, the drug, dose, route, and redosing interval that has controlled your crises, the ones that have not, allergies, red cell antibodies, your center's 24-hour number, and the signature of the hematologist who wrote it. Ask for it at the first visit, and ask that it be placed in the record of the hospital you would actually go to, which may not be the one the clinic sits in. Keep a printed copy and a photo on your phone.

Say this at triage, word for word if you need to: "I have sickle cell disease and I am in a vaso-occlusive crisis. I have an individualized pain plan from my hematologist. The ASH guideline calls for my first dose within an hour of arrival and reassessment every 30 to 60 minutes." Ask the triage nurse to note your arrival time and pain score. Then:

• Hand over the printed plan and ask that it be scanned into your chart.
• Give your center's number and ask the ER to call it. Centers expect these calls.
• If IV access is slow, ask about a subcutaneous or intranasal first dose.
• If the first dose has not come by the hour, ask for the charge nurse, then the patient advocate.
• Bring a companion who can repeat the ask, a medication list, and a phone charger.
• Do not leave without a documented reassessment and a written plan for the next 24 hours.

Every entry below comes from current FDA labeling or an FDA announcement. Hydroxyurea remains the first-line disease-modifying drug; the others are added for people who still have crises on it or cannot take it. A matched-donor blood and bone marrow transplant remains the established potentially curative option for some patients (NHLBI).

The Oxbryta withdrawal was for safety, not supply: the FDA's September 26, 2024 alert says Pfizer reported "a higher rate of vaso-occlusive crisis" and "more deaths in the Oxbryta treatment group as compared to the placebo group" in postmarketing studies. If you were on it, make sure something replaced it. Cost is the wall in front of gene therapy. The CMS Cell and Gene Therapy Access Model negotiates outcomes-based agreements with the two manufacturers on behalf of state Medicaid programs; the CMS model page, read August 25, 2026, lists 32 participating states plus the District of Columbia and Puerto Rico, with start dates between January 2025 and January 2026. If you have Medicaid in one of them, ask your center whether it is a treatment site. Our guide to the sickle cell gene therapy access gap covers what stands between approval and an infusion.

Start with the NASCC map and our hematology directory, and read the sickle cell disease condition page for complications and screening. If you are between pediatric and adult care right now, call the SCDAA helpline at (800) 421-8453 and ask for the nearest adult program and a navigator. Bring this page to the first visit and ask for the pain plan before you leave.